Cystic Fibrosis
Also known as: CF, Mucoviscidosis
Cystic fibrosis is a life-threatening inherited disorder that causes severe damage to the lungs, digestive system, and other organs by producing thick, sticky mucus that clogs airways and traps bacteria. It is caused by mutations in the CFTR gene and is most common among people of Northern European descent. While there is no cure, breakthrough CFTR modulator therapies have dramatically improved outcomes and life expectancy in recent years.
Last updated November 10, 2026
Understanding Cystic Fibrosis
Cystic fibrosis (CF) is an inherited disease in which a faulty CFTR protein fails to move chloride and bicarbonate across the surfaces of the lungs, pancreas, gut, sweat glands and reproductive tract, leaving thick, dehydrated secretions wherever mucus is made. It is autosomal recessive: a child has it only when both parents pass on a faulty copy, and about 1 in 25 to 30 people of European ancestry is a carrier. In the United States it affects close to 40,000 people and roughly 1 in 3,500 newborns of European descent, 1 in 17,000 Black newborns and 1 in 31,000 Asian American newborns; worldwide the figure is around 105,000. Every US state has screened newborns for CF since 2010, so most cases are found in the first weeks of life. The story of CF has changed faster than almost any disease in medicine: median predicted survival in the Cystic Fibrosis Foundation registry was about 31 years in 2002, is now over 60, and more than half of people with CF in the US are adults.
CFTR normally sits on the cell surface and secretes chloride, dragging water with it, and bicarbonate, which lets mucins unfold properly. Without it, the airway surface liquid shrinks, cilia collapse into sticky mucus, and the clearance system that sweeps inhaled bacteria out of the lungs stalls. Staphylococcus aureus and Hemophilus colonize first, Pseudomonas aeruginosa later, and the neutrophil response to chronic infection releases elastase that digests airway walls, producing bronchiectasis. Lung function, measured as FEV1, historically fell 1 to 3 percentage points a year, and lung disease causes the great majority of deaths. In the pancreas, thick secretions block the ducts before birth; about 85 percent of people are pancreatic insufficient, so fat, protein and the fat-soluble vitamins A, D, E and K are malabsorbed. The same process causes CF-related diabetes in about a third of adults and up to half by age 40, liver disease in 5 to 10 percent, and sweat that loses 3 to 5 times the normal amount of salt, which is the basis of the diagnostic sweat test.
Care is delivered by accredited CF centers with pulmonologists, dietitians, physiotherapists, pharmacists, social workers and psychologists, following Cystic Fibrosis Foundation guidelines, and this team is why survival has doubled. The single biggest advance is the CFTR modulators, which rescue the faulty protein: elexacaftor/tezacaftor/ivacaftor (Trikafta), approved in 2019, which in a 403-person phase 3 trial raised FEV1 by 14.3 percentage points, cut exacerbations by 63 percent and lowered sweat chloride by 41.8 mmol/L. It suits roughly 90 percent of people with CF from age 2; a once-daily successor, vanzacaftor/tezacaftor/deutivacaftor, was approved in 2024. The older pillars are all still recommended: daily airway clearance; inhaled dornase alfa, which cut exacerbations by about a quarter in its 1994 trial; inhaled 7 percent hypertonic saline, which reduced exacerbations by 56 percent over 48 weeks in 164 people; and azithromycin three times a week, which improved FEV1 by 4.4 percent and reduced exacerbations by 40 percent in a 2003 trial. Pancreatic enzyme replacement with every meal, a high-calorie diet and CF-specific vitamin preparations keep nutrition on track, and lung transplantation remains the end-stage option.
No supplement, herb or diet treats cystic fibrosis; the defect is in a single gene and nothing on a shelf corrects it. Even plausible products fail: curcumin corrected CFTR in mice and did nothing in people, inhaled glutathione failed to improve lung function in a 153-person trial, and colloidal silver, oregano oil and chlorophyll have no evidence at all. What looks like supplementation in CF is actually standard care prescribed and monitored by the CF team: pancreatic enzymes with every meal and snack, vitamins A, D, E and K in CF-specific formulations with yearly blood levels, and extra salt. They are listed below so you know what they are for; over-the-counter enzymes and ordinary multivitamins are not substitutes. Beyond standard care, the evidence is thin: oral N-acetylcysteine stabilized FEV1 over 24 weeks in one 70-person trial, probiotics may reduce exacerbations in low-certainty Cochrane evidence, and omega-3 fats have five small trials with hints of benefit. Any of these should go through the CF team, which also needs to know about St. John's wort and grapefruit, which change modulator blood levels.
The most common mistake today is the one success created: treating the modulator as a replacement for the rest of the routine. People who feel well on Trikafta drop airway clearance, skip hypertonic saline and let enzymes slide, and the first sign is a slow drift in FEV1 rather than a crash. The CF Foundation still recommends continuing airway clearance and inhaled therapies, and the SIMPLIFY trial, which tested stopping dornase alfa or hypertonic saline in well-controlled people on modulators, found no short-term harm over 6 weeks but was not designed to show long-term safety. Decide what to stop with your center, not alone. A second and newer mistake is the diet: for decades people with CF were told to eat as many calories and as much fat as possible, and on modulators absorption improves, appetite returns and overweight and obesity now affect roughly a third of adults with CF. The high-fat prescription needs revisiting with the dietitian once BMI passes the target, not abandoned for a restrictive diet that risks the malnutrition it was designed to prevent.
At a Glance
- Common symptoms
- Persistent cough with thick mucus, Frequent lung infections (pneumonia, bronchitis), Wheezing and shortness of breath
- Main treatments
- CFTR modulator therapies (elexacaftor/tezacaftor/ivacaftor—Trikafta), Airway clearance techniques (chest physiotherapy, vest therapy), Inhaled mucolytics (dornase alfa) and hypertonic saline
- Category
- Genetic · Affects approximately 40,000 people in the U.S. and 100,000 worldwide
- See a doctor if
- Your newborn has a positive CF screening result
Symptoms
Causes
- Mutations in the CFTR gene (over 2,000 known mutations; F508del most common)
- Autosomal recessive inheritance (both parents must carry a mutation)
- Defective CFTR protein leads to abnormal chloride and water transport
Risk Factors
- Both parents carrying a CFTR gene mutation
- Northern European ancestry (highest carrier rate: 1 in 25)
- Family history of cystic fibrosis
Diagnosis
- Newborn screening (immunoreactive trypsinogen blood test)
- Sweat chloride test (gold standard; chloride > 60 mmol/L confirms CF)
- Genetic testing for CFTR mutations
- Pulmonary function tests to assess lung function
- Pancreatic function tests
Treatment
- CFTR modulator therapies (elexacaftor/tezacaftor/ivacaftor—Trikafta)
- Airway clearance techniques (chest physiotherapy, vest therapy)
- Inhaled mucolytics (dornase alfa) and hypertonic saline
- Inhaled antibiotics (tobramycin) for chronic Pseudomonas infection
- Pancreatic enzyme replacement therapy (PERT) with meals
- Lung transplantation for end-stage lung disease
Natural remedies for cystic fibrosis: what the evidence says
Ranked by the strength of human evidence for cystic fibrosis specifically. These sit alongside medical care, not in place of it.
Pancreatic Enzymes (prescription PERT)
Strong evidenceAbout 85 percent of people with CF cannot digest fat and protein without pancreatic enzyme replacement therapy, and PERT is the reason growth and nutrition normalized in the modern era: randomized trials of FDA-approved pancrelipase products raise fat absorption from roughly 50 to 60 percent of intake to about 85 to 90 percent. It is dosed by weight and fat intake and is prescription treatment, not a supplement. Over-the-counter 'digestive enzyme' products are unregulated, far weaker and have no place in CF.
- Studied dose
- Per CF Foundation guidance: 500 to 2,500 lipase units per kg per meal (about half with snacks), not exceeding 10,000 units per kg per day, taken at the start of eating; prescription products only.
- Cautions
- Doses above 6,000 units per kg per meal have caused fibrosing colonopathy, a scarring of the large bowel. Most products are pork-derived, so pork allergy matters; persistent greasy stools or bloating usually mean the dose or timing needs adjusting by the team.
Vitamin D
Strong evidenceVitamin D is malabsorbed in CF, and low levels track with worse bone density and more exacerbations in registry data. The CF Foundation's 2012 guideline sets a target blood level of at least 30 ng/mL and recommends routine supplementation for everyone with CF, checked yearly. Whether higher dosing changes lung outcomes is less clear: a small trial of a single 250,000 IU dose in hospitalized adults reduced 1-year hospitalization, but a larger multicenter follow-up trial did not confirm a benefit on exacerbations.
- Studied dose
- Per CF Foundation: 400 to 500 IU daily under 1 year, 800 to 1,000 IU from 1 to 10, 800 to 2,000 IU over 10, as vitamin D3 in a CF-specific vitamin; the team raises it to reach 30 ng/mL, up to 10,000 IU a day in adults.
- Cautions
- Excess causes high calcium and kidney stones; levels are monitored, so do not add extra vitamin D on your own. Rifampin, phenytoin and some HIV drugs lower vitamin D.
Vitamin A
Moderate evidenceFat malabsorption makes vitamin A deficiency common in untreated CF, with night blindness and worse lung function in deficient children in older studies, so routine supplementation is CF Foundation standard. The catch is that CF-specific vitamins already contain high doses, and reports of vitamin A excess, with bone pain and raised liver enzymes, have appeared in adults on modulators whose absorption suddenly improved.
- Studied dose
- Through a CF-specific vitamin only, typically 1,500 to 10,000 IU a day by age, with blood retinol checked annually; no separate retinol supplements.
- Cautions
- Toxic in excess and harmful to a fetus above 10,000 IU a day in pregnancy; avoid cod liver oil and standalone retinol. Beta-carotene is safer but is not a replacement in CF.
Vitamin E
Moderate evidenceVitamin E deficiency in CF causes hemolytic anemia in infants and, if prolonged, nerve damage, and low levels are linked to more frequent exacerbations and faster lung decline in cohort studies. Supplementation is CF Foundation standard; the evidence base is observational and physiological rather than large randomized trials.
- Studied dose
- Per CF Foundation: 40 to 50 IU daily in infants, 80 to 150 IU from 1 to 3, 100 to 200 IU from 4 to 8, and 200 to 400 IU from 8 upward, as part of a CF-specific vitamin.
- Cautions
- High doses add to the effect of warfarin and other blood thinners; the vitamin K in CF vitamins partly offsets this, but report easy bruising to the team.
Omega-3 Fatty Acids
Preliminary evidenceA 2020 Cochrane review found five trials with 106 participants comparing omega-3 fats with placebo in CF; some reported improved lung function and lower sputum inflammatory markers, with fewer antibiotic courses in one, but the trials were short and small and the review rated the evidence insufficient. People with CF have abnormally high arachidonic acid and low DHA in cell membranes, which is the rationale.
- Studied dose
- Trials used 1 to 4 g of combined EPA and DHA daily for 6 weeks to 12 months, taken with enzymes.
- Cautions
- Loose stools and fishy taste; take with enzymes since it is fat; a mild bleeding tendency above 3 g a day.
Lactobacillus Rhamnosus GG
Preliminary evidenceIn a 6-month crossover trial in 38 children with CF, LGG reduced pulmonary exacerbations and hospital admissions compared with placebo, and a 2020 Cochrane review of 12 trials (464 people) concluded probiotics may reduce exacerbations and improve gut symptoms, but with low-certainty evidence and no effect on lung function.
- Studied dose
- 10 billion CFU of LGG daily; trials ran 1 to 12 months.
- Cautions
- Avoid with central venous catheters and severe immunosuppression, including the months after transplant; separate from oral antibiotics by 2 hours.
N-Acetylcysteine (NAC)
Preliminary evidenceOral N-acetylcysteine at 900 mg three times daily for 24 weeks kept FEV1 stable while it fell in the placebo group in a 70-person randomized trial, a difference of roughly 150 mL, though sputum inflammatory markers did not change. An earlier Cochrane review found no clear benefit from lower doses, so the evidence is preliminary.
- Studied dose
- 900 mg three times daily (2,700 mg a day) was the trial dose; lower doses showed nothing.
- Cautions
- Nausea, heartburn and a sulfur smell; can mildly thin the blood, so caution with anticoagulants; the 2,700 mg dose should be agreed with the CF team.
What matters day to day
- Do airway clearance once or twice every day, including the days you feel well: the CF Foundation recommends it for everyone with CF regardless of modulator use, because mucus that is not moved becomes the next infection.
- Exercise for at least 30 minutes most days: higher physical activity is associated with slower FEV1 decline in registry cohorts, and aerobic exercise loosens mucus, strengthens breathing muscles and protects bone density.
- Keep at least 6 feet from other people with CF and never share nebulizers or airway clearance equipment: the CF Foundation infection-control guideline exists because epidemic strains of Pseudomonas, Burkholderia and MRSA spread between patients, and some of them are untreatable.
- Add salt and fluid in heat and during exercise: sweat in CF loses 3 to 5 times the normal sodium, and the Foundation recommends salting food freely, salty snacks, and for infants about an eighth of a teaspoon of salt a day.
- Keep the annual screens: an oral glucose tolerance test from age 10 for CF-related diabetes, because A1c misses it in CF; a bone density scan from age 18; liver tests; and the yearly depression and anxiety screen, since each affects roughly 1 in 5 adults with CF and both worsen adherence.
- Avoid all smoke, including secondhand and vaping: children with CF exposed to household smoke have measurably lower lung function and more exacerbations than those who are not.
Prevention
- Genetic counseling for carriers and affected families
- Carrier screening before or during pregnancy
- Newborn screening enables early diagnosis and treatment
When to See a Doctor
- Your newborn has a positive CF screening result
- Your child has recurrent respiratory infections or poor growth
- You or your partner have a family history of CF and are planning a pregnancy
- A child or adult with CF experiences worsening respiratory symptoms
Frequently Asked Questions
References
- Middleton PG, Mall MA, Drevinek P, et al.. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. New England Journal of Medicine (2019)
- Elkins MR, Robinson M, Rose BR, et al.. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine (2006)
- Fuchs HJ, Borowitz DS, Christiansen DH, et al.. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine (1994)
- Tangpricha V, Kelly A, Stephenson A, et al.. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. Journal of Clinical Endocrinology and Metabolism (2012)
- Coffey MJ, Garg M, Homaira N, et al.. Probiotics for people with cystic fibrosis. Cochrane Database of Systematic Reviews (2020)
- Watson H, Stackhouse C. Omega-3 fatty acid supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews (2020)
- Conrad C, Lymp J, Ishihara V, et al.. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. Journal of Cystic Fibrosis (2015)
- Mayer-Hamblett N, Ratjen F, Russell R, et al.. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respiratory Medicine (2023)
- Cystic Fibrosis Foundation. 2023 Patient Registry Annual Data Report (2024)
- National Heart, Lung, and Blood Institute. Cystic Fibrosis (2024)View source
Related Conditions
Lab tests that relate to cystic fibrosis
Related Reading
Have questions about Cystic Fibrosis?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.